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Abstract 
Purpose: To identify clinically significant potential drug-drug interactions in cardiac intensive care units 
of two tertiary care hospitals in Peshawar, Pakistan, and to compare the various potential drug-drug 
interactions related parameters between the government and private hospitals included in the study. 
Method: A prospective study was conducted in the cardiac intensive care units of the two hospitals, viz, 
Lady Reading Hospital Peshawar (LRH) and Northwest General Hospital and Research Center 
Peshawar (NWGH &RC), which are government and private hospitals, respectively. Samples of 260 
and 250 patients from LRH and NWGH & RC, respectively, were evaluated. Patient medication charts 
were evaluated for potential drug-drug interactions and clinically significant potential drug-drug 
interactions using Micromedex DrugReax. The data were statistically analyzed.   
Results: A high prevalence of potential drug-drug interactions was reported in both hospitals: 92 and 
96.9 % in Northwest General Hospital and Research Center, and Lady Reading Hospital, respectively, 
of which half were clinically significant. A total of 19 interacting drug pairs contributed to the clinically 
significant potential drug-drug interactions. Independent sample t-test showed a significant difference in 
the potential drug-drug interactions of both hospitals. Furthermore, a significant relationship was found 
between the number of potential drug-drug interactions, on the one hand, and the number of prescribed 
drugs and age, on the other. 
Conclusion: A high prevalence of potential drug-drug interactions, particularly clinically significant 
potential drug-drug interactions, calls for proper identification of these interactions and monitoring of 
patients to minimize adverse outcomes and improve patient therapy. 
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Cardiovascular diseases are a prime cause of 
high mortality rates throughout the world. In 
2012, World Health Organization (WHO) 
estimated that 17.5 million people died worldwide 
due to cardiovascular diseases. Most of these 
deaths occurred in low or middle income 
countries [1]. Risk factors include diseases like 
hypertension, hyperlipidemia, diabetes or other 
diseases which require multiple drug therapy, 
while behavioral risk factors include unhealthy 
diet, tobacco use, lack of physical activity and 
stress [2,3]. Furthermore, treatment for these 
diseases require multiple drug administration 
which when combined with factors like advanced 
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age, co-morbidities and changes in hepatic and 
renal functions, increases the risk of potential 
drug-drug interactions (PDDIs) [4-6]. 
 
The presence of a potential drug-drug interaction 
(PDDIs) is highly probable in critical units like 
cardiac intensive care units (CCU), primarily due 
to the multiple drug therapy employed to combat 
the complex disease condition of the patient 
along with co-morbidities and age which further 
increases the risk of PDDIs [7,8]. However, not 
all the PDDIs are clinically significant and are not 
a predisposition of an adverse clinical event. 
Some PDDIs are employed to benefit the patient 
but these are very limited, for example the use of 
aspirin and clopidogrel in patients to prevent 
thromboembolism [9,10]. Apart for some rare 
instances, PDDIs are one of the leading causes 




This prospective cross sectional study was 
carried out in CCUs of two tertiary care hospitals 
of Peshawar, Lady Reading Hospital (LRH) and 
Northwest General Hospital and Research 
Center Peshawar (NWGH & RC). LRH is a 
government tertiary care hospital while NWGH is 
a private hospital. The duration of the study was 
one year and was approved by the ethical 
committees of both hospitals vide letter number 
010 and NWGH/Research/01, respectively. 
Patient demographics, duration of stay, 
diagnosis, drugs administered, dose, frequency 
and duration of drugs prescribed were recorded 
from the medication chart of the patient. Names 
of the patients, their identification numbers and 
medical records were kept confidential. Good 
clinical practice (GCP) guidelines were followed 
under the declaration of Helsinki (1964) by the 
International Conference on Harmonization and 
Nuremburg Code [26]. Patients admitted to the 
CCU for at least 24 h and prescribed at least 2 
drugs were included in the study. 
 
Micromedex database DrugReax [13] was used 
to analyze the potential drug-drug interactions 
among prescribed drugs to the patients. This 
database provides information on the clinical 
effect, severity, documentation, onset and 
mechanism of the PDDIs. Severity may be major, 
moderate or minor; documentation may be 
excellent, good or fair; onset may be rapid, 
delayed or unknown; nature of PDDIs may be 
pharmacokinetic, pharmacodynamic or unknown; 
while mechanisms of PDDIs include absorption, 
distribution, metabolism, elimination, synergism, 
antagonism or unknown. 
 
The severity and documentation of the PDDIs 
reported in Micromedex DrugReax was used to 
create a list of clinically significant PDDIs, on the 
basis of which the following PDDIs were 
considered as clinically significant: 
 
• PDDIs having severity of major and of 
excellent or good documentation  
 
• PDDIs having severity of moderate and of 
excellent or good documentation 
 
Frequencies were used to summarize gender, 
number of prescribed drugs, diagnosis, duration 
of stay, frequency of PDDIs, interacting drug 
pairs and their severity, documentation, onset 
and clinical significance. Multiple linear 
regression was used to determine the 
relationship between number of prescribed 
drugs, duration of stay and the number of PDDIs. 
P values of ˂ 0.05 was considered statistically 
significant. Independent samples t test was 
performed to the compare the means of clinically 
significant PDDIs in both hospitals. All the 
analysis was performed using IBM SPSS 
Statistics for Windows, Version 20 (Armonk, NY: 






A total of 510 patient prescriptions were 
evaluated, of which 250 were from NWGH & RC, 
while 260 were from LRH, representing private 
and government sector respectively. The 
proportion of male patients as compared to 
female patients was higher in both the hospitals, 
59.2 % in NWGH & RC while 66.2 % in LRH. The 
mean age of the patients was 58.06 ± 12.75 
(range 19 - 88) and 55.24 ± 13.58 (range 12 - 95) 
in NWGH & RC and LRH, respectively. The 
median duration of stay was 3 days for both 
hospitals while the median number of drugs 
prescribed was higher in NWGH & RC (6 drugs 
per prescription) as compared to LRH (5 drugs 
per prescription). The general characteristics of 




The most frequent diagnosis of patients admitted 
in both NWGH &RC and LRH was myocardial 
infarction (MI), while acute coronary syndrome 
(ACS) and heart failure were the other most 
frequent diagnosis of the patients. The 
comparison of the percentage of diagnosis in 
both hospitals is displayed in Figure 1. 
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Table 1: General patient characteristics in CCU of NWGH and LRH 
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Figure 1: Comparison of diagnosis between NWGH & RC and LRH 
 
Prevalence of PDDIs and categories 
 
At least one potential drug-drug interaction 
(PDDI) was encountered in 92 and 96.9 % of the 
patients in NWGH &RC and LRH, respectively. A 
total of 105 interacting drug pairs contributed to 
the 909 PDDIs encountered in NWGH &RC while 
76 interacting drug pairs contributed to the 1204 
PDDIs encountered in LRH. The severity, 
documentation, onset, nature and mechanism of 
the PDDIs encountered in both hospitals are 
displayed in Table 2. 
 
Clinically significant PDDIs 
 
Clinically significant PDDIs were identified using 
the predetermined criteria. Using this criteria 
along with the frequency of PDDIs, a list of 19 
interacting drug pairs was prepared from both the 
hospitals which were considered to be significant 
clinically, because of the associated high risk and 
occurrence in the cardiac critical care unit. The 
list of clinically significant PDDIs from both 
hospitals along with their frequencies and 
potential outcome is displayed as Table 3. These 
PDDIs contributed to 44.6 and 51 % of the total 
PDDIs encountered in NWGH & RC and LRH 
respectively. Furthermore, it was observed that 
3.63 and 4.63 PDDIs were present per patient in 
NWGH & RC and LRH respectively while 2.07 
and 2.54 clinically significant PDDIs were present 
per patient in the hospitals respectively. 
 
Independent sample t-test 
 
An independent sample t-test was performed to 
compare the means of clinically significant PDDIs 
between NWGH and LRH. The t-test showed a 
significant difference (t = 3.435, p = 0.001) in the 
number of clinically significant PDDIs between 
NWGH and LRH. 
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Table 2: Categories of Potential drug-drug interactions in NWGH and LRH 
 
Variable Frequency (%) NWGH Frequency (%) LRH 










































































Table 3: Clinically significant PDDIs in NWGH and LRH 
 
























































































Increased risk of bleeding. 
Reduction in clinical efficacy of clopidogrel and increased 
risk for thrombosis. 
May result in hyperkalemia. 
May result in increased digoxin exposure. 
May result in decreased antihypertensive effect. 
May result in an increase in nitroglycerin concentrations and 
additive platelet function depression. 
May result in postural hypotension (first dose). 
May result in decreased diuretic and antihypertensive 
efficacy.  
May result in reduced diuretic effectiveness, hyperkalemia, 
or possible nephrotoxicity. 
May result in decreased antihypertensive effect. 
May result in decreased antihypertensive effect. 
May result in decreased antihypertensive effects and an 
increased risk of renal impairment. 
May result in decreased antihypertensive effects and an 
increased risk of renal impairment. 
May result in decreased antihypertensive effects and an 
increased risk of renal impairment. 
Decreased diuretic and antihypertensive efficacy. 
May result in digoxin toxicity (nausea, vomiting, cardiac 
arrhythmias). 
May result in decreased lisinopril effectiveness. 
Increased risk of hypoglycemia. 
Decreased formation of clopidogrel active metabolite 
resulting in high on-treatment platelet reactivity. 
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Table 4: Prediction of clinically significant PDDIs 
 
No. of clinically significant 
PDDIs 
Coefficient Standard error t P-value 
Constant 
No. of prescribed drugs 



















Prediction of clinically significant PDDIs 
 
Multiple linear regression model was fitted to 
predict the number of clinically significant PDDIs 
based on number of prescribed drugs, duration 
of stay and age. The effect of number of 
prescribed drugs on number of clinically 
significant PDDIs, controlling for the effect of 
duration of stay and age, was found to be 
significant. (t = 13.795, p < 0.0001). The effect of 
age on number of clinically significant PDDIs, 
controlling for the effect of duration of stay and 
number of prescribed drugs, was also found to 
be significant. (t = -3.196, p = 0.001). The effect 
of duration of stay on number of clinically 
significant PDDIs, controlling for the effect of 
number of prescribed drugs and age, was found 





This study reported a high prevalence of PDDIs 
which corresponds to other studies reporting a 
similar higher prevalence in cardiology. 
University of Pittsburg conducted a study in 
cardiac and cardiothoracic ICU patients, found 
87.7 % patients having at least a single PDDI 
[15]. Cross sectional studies conducted in 
Pakistan also reported a prevalence of 91.1 and 
77.5 % cardiology patients having a PDDI [4,16]. 
It was also reported that 72.5 % of ICU patients 
had PDDIs in the ICU of a Brazilian hospital [17]. 
While another Brazilian study reported 87.2 % 
patients in cardiology encountered a PDDI [18]. 
 
A Brazilian study evaluated 1785 prescriptions 
and recorded similar trends as seen in this study 
with the severity of most PDDIs being moderate 
(78.6 %), documentation of most PDDIs was 
good (29.5 %) and most (42.5 %) were 
pharmacodynamics in nature [19] Another study 
reported PDDIs of moderate severity to be the 
most common (62.5 %) [20]. In 203 patients, 
75.03 % of PDDIs were in Category C which 
corresponds to moderate severity [21]. A record 
of 1124 patients were evaluated for PDDIs at 24 
h and 120 h after admission to the hospital. The 
severity of most interactions was moderate in 
both the time frames (50.1 and 51.4 %), most of 
the interactions were good documentation (63.9 
and 59.1 %) and most of were of 
pharmacodynamic in nature at 120 h (45.2 %) 
[22]. To our knowledge no previous study has 
focused on the clinically significant interaction in 
cardiac intensive care units. Our study shows 
that 3.63 and 4.63 PDDIs were present per 
patient in NWGH & RC and LRH respectively 
while 2.07 and 2.54 clinically significant PDDIs 
were present per patient in the hospitals 
respectively. This is of great concern because 
more than half of the PDDIs encountered were 
clinically significant and can have a significant 
impact on the advanced disease condition of the 
patient. 
 
A significant association was found between 
clinically significant PDDIs and number of 
prescribed drugs and age of the patient. This 
association was similar to that of reported in 
other studies [4,18,23-25]. A Nepalese study 
reported a significant linear association between 
length of stay and occurrence of PDDIs [20]. 
Another study conducted in cardiology 
department of Pakistan also reported a 
significant association between PDDIs and 
prescribed drugs and age [4]. 
 
Proper PDDIs identification and management 
system are lacking in these hospitals which 
contribute to this high prevalence of PDDIs. 
Pharmacists should update themselves 
regarding the knowledge of clinically significant 
PDDIs and timely interventions implemented. 
 
Limitations of the study 
 
Monitoring of the adverse outcomes due to the 
PDDIs and lack of interventions were some of 
the limitations of this study. This study identified 
clinically significant PDDIs on the basis of 
literature and drug interaction database, while 
clinical studies can be conducted in the future to 
monitor the actual clinically notable adverse 





This study identified not only a high prevalence 
of PDDIs but also clinically significant PDDIs 
which have greater potential for significant 
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changes in patients’ condition. Also notable was 
the significant difference in PDDIs between the 
private and government hospital, which demands 
for the implementation of proper drug interaction 
monitoring systems across all hospitals to 
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